Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 283

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 283
---
 |          0.5 |   |
| Fair value    |     | $ |          402 |   |     | $ |          407 |   |

<div align='center'>F-34</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | WARRANT LIABILITY (Cont.) |

The following table presents changes in
the fair value of the warrant liability:

| Balance as of January 1, 2022   |     | $ | 137 |   |
| Changes in fair value           |     |   | 270 |   |
| Balance as of December 31, 2022 |     | $ | 407 |   |
| Changes in fair value           |     |   |  (5 | ) |
| Balance as of December 31, 2023 |     | $ | 402 |   |

The Company has performed a sensitivity
analysis of the warrant liability which is classified as level 3 financial instruments in the fair value hierarchy. The Company recalculated
the value of the warrants by applying a +/- 5.0% changes to the input variables in PWERM. As of December 31, 2023, a 5.0% decrease in
discount rate would increase the fair value of the warrants to $408; a 5.0% increase in discount rate would decrease the fair value of
the warrants to $397.

| NOTE 8:- | TAXES ON INCOME |

| a. | Tax rates applicable to the Company: |

| b. | Net operating loss carry forward: |

As of December 31, 2023, the Company had
net operating loss carry forwards and capital loss carry forward for Israeli income tax purposes of approximately $39,800 and $117, respectively. Net
operating loss carry forwards in Israel may be carried forward indefinitely and offset against future taxable income.

| d. | Deferred income taxes: |

Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes.

<div align='center'>F-35</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 8:- | TAXES ON INCOME (Cont.) |

Significant